There is a significant number of clinical trials testing the combination of A2ARs with anti-cancer immunotherapies and, eventually, adding inhibitors of the enzyme that converts AMP to adenosine (CD73/5′-nucleotidase, see Figure 1B). Here, NT5E is linked to cancer.